about
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...
Read More
37.51
-0.23
(-0.61%)
1.3M
XNAS Volume
High vol. this week
XNAS 10 Sep, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for Pharvaris NV is on 16 Sep 2026 for the purpose of H.C. Wainwright 28th Annual Global Investment Conference
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Pharvaris NV Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..